Bridged Bicyclo Compounds, Heterocyclic
"Bridged Bicyclo Compounds, Heterocyclic" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Heterocyclic compounds that contain two rings that share two non-adjacent atoms in common.
| Descriptor ID |
D019086
|
| MeSH Number(s) |
D03.605.084
|
| Concept/Terms |
Bridged Bicyclo Compounds, Heterocyclic- Bridged Bicyclo Compounds, Heterocyclic
- Bicyclo Compounds, Heterocyclic
- Heterocyclic Bicyclo Compounds
- Bicyclic Heterocyclic Compounds
- Heterocyclic Compounds, Bicyclic
- Heterocyclic Cpds, Bicyclic
- Bicyclic Heterocyclic Cpds
|
Below are MeSH descriptors whose meaning is more general than "Bridged Bicyclo Compounds, Heterocyclic".
Below are MeSH descriptors whose meaning is more specific than "Bridged Bicyclo Compounds, Heterocyclic".
This graph shows the total number of publications written about "Bridged Bicyclo Compounds, Heterocyclic" by people in this website by year, and whether "Bridged Bicyclo Compounds, Heterocyclic" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1991 | 1 | 0 | 1 |
| 1992 | 3 | 0 | 3 |
| 1993 | 2 | 0 | 2 |
| 1994 | 1 | 0 | 1 |
| 1995 | 3 | 0 | 3 |
| 1996 | 3 | 0 | 3 |
| 1997 | 0 | 1 | 1 |
| 1999 | 1 | 0 | 1 |
| 2000 | 3 | 0 | 3 |
| 2002 | 0 | 2 | 2 |
| 2003 | 0 | 1 | 1 |
| 2005 | 0 | 1 | 1 |
| 2006 | 1 | 0 | 1 |
| 2007 | 1 | 3 | 4 |
| 2008 | 1 | 0 | 1 |
| 2009 | 0 | 2 | 2 |
| 2010 | 1 | 0 | 1 |
| 2014 | 0 | 1 | 1 |
| 2017 | 1 | 0 | 1 |
| 2020 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Bridged Bicyclo Compounds, Heterocyclic" by people in Profiles.
-
Ramraj SK, Elayapillai SP, Pelikan RC, Zhao YD, Isingizwe ZR, Kennedy AL, Lightfoot SA, Benbrook DM. Novel ovarian cancer maintenance therapy targeted at mortalin and mutant p53. Int J Cancer. 2020 08 15; 147(4):1086-1097.
-
Lin SF, Lin JD, Hsueh C, Chou TC, Wong RJ. A cyclin-dependent kinase inhibitor, dinaciclib in preclinical treatment models of thyroid cancer. PLoS One. 2017; 12(2):e0172315.
-
Rad AT, Ali N, Kotturi HS, Yazdimamaghani M, Smay J, Vashaee D, Tayebi L. Conducting scaffolds for liver tissue engineering. J Biomed Mater Res A. 2014 Nov; 102(11):4169-81.
-
Zhang M, Song P, Xu J, Zou MH. Activation of NAD(P)H oxidases by thromboxane A2 receptor uncouples endothelial nitric oxide synthase. Arterioscler Thromb Vasc Biol. 2011 Jan; 31(1):125-32.
-
Song P, Zhang M, Wang S, Xu J, Choi HC, Zou MH. Thromboxane A2 receptor activates a Rho-associated kinase/LKB1/PTEN pathway to attenuate endothelium insulin signaling. J Biol Chem. 2009 Jun 19; 284(25):17120-17128.
-
Uriarte SM, Jog NR, Luerman GC, Bhimani S, Ward RA, McLeish KR. Counterregulation of clathrin-mediated endocytosis by the actin and microtubular cytoskeleton in human neutrophils. . 2009 Apr; 296(4):C857-67.
-
Amagata T, Johnson TA, Cichewicz RH, Tenney K, Mooberry SL, Media J, Edelstein M, Valeriote FA, Crews P. Interrogating the bioactive pharmacophore of the latrunculin chemotype by investigating the metabolites of two taxonomically unrelated sponges. J Med Chem. 2008 Nov 27; 51(22):7234-42.
-
Zhang M, Dong Y, Xu J, Xie Z, Wu Y, Song P, Guzman M, Wu J, Zou MH. Thromboxane receptor activates the AMP-activated protein kinase in vascular smooth muscle cells via hydrogen peroxide. Circ Res. 2008 Feb 15; 102(3):328-37.
-
Patterson E, Scherlag BJ, Lazzara R, Garrison GL, Berlin KD. Electrophysiologic actions of d,l-sotalol and GLG-V-13 in ischemically injured canine epicardium. J Cardiovasc Pharmacol. 2007 Sep; 50(3):304-13.
-
Jog NR, Jala VR, Ward RA, Rane MJ, Haribabu B, McLeish KR. Heat shock protein 27 regulates neutrophil chemotaxis and exocytosis through two independent mechanisms. J Immunol. 2007 Feb 15; 178(4):2421-8.